ODN 1018 VacciGrade™
-
Cat.code:
vac-1018-1
- Documents
ABOUT
CpG ODN, type B (human/mouse) - TLR9-based vaccine adjuvant
ODN 1018 Vaccigrade™ is a synthetic immunostimulatory oligonucleotide (ODN) that contains unmethylated CpG dinucleotides. This class B CpG ODN is characterized by a fully phosphorothioate-modified backbone (nuclease resistant). It contains CpG motifs that are able to bind and activate both rodent and human Toll-like receptor 9 (TLR9) [1]. ODN 1018 VacciGrade™ has an identical sequence to 1018 ISS.
ODN 1018 VacciGrade™ successfully activates the TLR9-dependent NF-κB pathway in HEK-Blue mTLR9 cells, expressing mouse TLR9 (mTLR9), but not in HEK-Blue hTLR9 cells, expressing human TLR9 (hTLR9). (see figure). ODN 1018 VacciGrade™ is a high-quality pre-clinical grade, suitable for in vivo use.
ODN 1018 VacciGrade™ is for research use only, and not for human or veterinary use. It is not a pharmaceutical preparation fit for vaccine manufacturing.
1. Campbell JD, 2017. Development of the CpG Adjuvant 1018: A Case Study. Methods Mol Biol. 1494:15-27.
VacciGrade™
VacciGrade™ is a high-quality pre-clinical grade, suitable for in vivo studies. VacciGrade™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room. The absence of bacterial contamination is assessed by a sterility test using a pharmacopeia-derived assay.
SPECIFICATIONS
Specifications
TLR9
5′-tgactgtgaacgttcgagatga-3' (22 mer)
Note: Regular letters represent phosphorothioate bonds, bold letters represent CpG dinucleotides
3 - 50 μg/mouse
2 mg/ml in physiological water
Sterility guaranteed
< 1 EU/mg (measurement by kinetic chromogenic LAL assay)
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:ODN 1018 VacciGrade™
-
Cat code:vac-1018-1
-
Quantity:1 mg
10 ml sterile endotoxin-free physiological water (NaCl 0.9%)
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
CpG ODNs
Synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG ODNs) have been extensively studied as adjuvants [1]. These CpG motifs are present at a 20-fold greater frequency in bacterial DNA compared to mammalian DNA [2]. CpG ODNs are recognized by the Toll-like receptor 9 (TLR9), which is expressed on human B cells and plasmacytoid dendritic cells (pDCs), thereby inducing Th1-dominated immune responses [3]. Pre-clinical studies, conducted in rodents and non-human primates, as well as human clinical trials, have demonstrated that CpG ODNs can significantly improve vaccine-specific antibody responses [1]. Three types of stimulatory CpG ODNs have been identified, types A, B, and C, which differ in their immune-stimulatory activities [4-5].
1018 ISS
1018 immunostimulatory sequence (ISS) is a type B CpG ODN with the sequence 5′-TGACTGTGAACGTTCGAGATGA-3′. It mimics bacterial single-stranded (ss) DNA to activate innate immunity through binding to TLR9. The first CpG motif (underlined) is a sequence active on mouse TLR9, whereas the second CpG motif (bold) is active on human and non-human primate TLR9 [6]. Type B CpG ODNs contain a full phosphorothioate backbone with one or more CpG dinucleotides and were described to strongly activate the Th1 cell and B cell populations [4,6]. CpG motifs present in the 1018 sequence stimulate the innate immune system, which results in efficacious immunological effects, such as the production of IL-12, IL-18, and IFN-γ from macrophages and natural killer (NK) cells, promoting Th1 responses, and its involvement in antibody production and B cell proliferation [7]. The GMP-produced CpG 1018® produced by Dynavax Technologies is currently the only FDA-approved CpG adjuvant for human vaccine use. It is a component of several approved vaccines, including the licensed hepatitis B virus vaccine HEPLISAV-B® [8].
Note: CpG 1018® is a registered trademark of Dynavax Technologies and is used for comparative purposes only. ODN 1018 VacciGrade™ is not made by, affiliated with, sponsored by, or endorsed by Dynavax Technologies.
References:
1. Steinhagen F. et al., 2011. TLR-based immune adjuvants. Vaccine 29(17):3341-55.
2. Hemmi H. et al., 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-5.
3. Coffman RL. et al., 2010. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4):492-503.
4. Krug A. et al., 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol, 31(7): 2154-63.
5. Marshall JD. et al., 2005. Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol. 24(2):63-72.
6. Campbell JD, 2017. Development of the CpG Adjuvant 1018: A Case Study. Methods Mol Biol. 1494:15-27.
7. Eng NF, et al., 2013. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review. Hum Vaccin Immunother.(8):1661-72.
8. Strohmeier S, et al., 2022. A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice. NPJ Vaccines. 2022 Jul 22;7(1):81.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?